ProQR Therapeutics Statistics
Share Statistics
ProQR Therapeutics has 105.21M
shares outstanding. The number of shares has increased by 28.84%
in one year.
| Shares Outstanding | 105.21M |
| Shares Change (YoY) | 28.84% |
| Shares Change (QoQ) | 1.95% |
| Owned by Institutions (%) | 54.38% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 162,156 |
| FTD / Avg. Volume | 27.28% |
Short Selling Information
The latest short interest is 376.04K, so 0.36% of the outstanding
shares have been sold short.
| Short Interest | 376.04K |
| Short % of Shares Out | 0.36% |
| Short % of Float | 0.46% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -7.53 and the forward
PE ratio is -3.23.
ProQR Therapeutics's PEG ratio is
2.63.
| PE Ratio | -7.53 |
| Forward PE | -3.23 |
| PS Ratio | 11.05 |
| Forward PS | 1.5 |
| PB Ratio | 2.36 |
| P/FCF Ratio | -5.53 |
| PEG Ratio | 2.63 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ProQR Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.95,
with a Debt / Equity ratio of 0.19.
| Current Ratio | 3.95 |
| Quick Ratio | 3.95 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.71 |
| Debt / FCF | -0.46 |
| Interest Coverage | -28.29 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $113,885.54 |
| Profits Per Employee | $-167,246.99 |
| Employee Count | 166 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -197K |
| Effective Tax Rate | 0.7% |
Stock Price Statistics
The stock price has increased by -15.98% in the
last 52 weeks. The beta is 0.35, so ProQR Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -15.98% |
| 50-Day Moving Average | 1.5 |
| 200-Day Moving Average | 2.3 |
| Relative Strength Index (RSI) | 53.43 |
| Average Volume (20 Days) | 594,333 |
Income Statement
In the last 12 months, ProQR Therapeutics had revenue of 18.91M
and earned -27.76M
in profits. Earnings per share was -0.34.
| Revenue | 18.91M |
| Gross Profit | 18.91M |
| Operating Income | -30.47M |
| Net Income | -27.76M |
| EBITDA | -24.12M |
| EBIT | -26.88M |
| Earnings Per Share (EPS) | -0.34 |
Full Income StatementBalance Sheet
The company has 149.41M in cash and 17.22M in
debt, giving a net cash position of 132.19M.
| Cash & Cash Equivalents | 149.41M |
| Total Debt | 17.22M |
| Net Cash | 132.19M |
| Retained Earnings | -427.16M |
| Total Assets | 151.69M |
| Working Capital | 104.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -36.39M
and capital expenditures -1.42M, giving a free cash flow of -37.81M.
| Operating Cash Flow | -36.39M |
| Capital Expenditures | -1.42M |
| Free Cash Flow | -37.81M |
| FCF Per Share | -0.46 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -161.18% and -146.86%.
| Gross Margin | 100% |
| Operating Margin | -161.18% |
| Pretax Margin | -147.9% |
| Profit Margin | -146.86% |
| EBITDA Margin | -127.6% |
| EBIT Margin | -161.18% |
| FCF Margin | -200.01% |
